This article is more than 5 years old. Information may no longer be current.

Implandata begins trial of continual IOP monitoring sensor

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Implandata Ophthalmic Products has begun a clinical study of its novel pressure sensor for continual monitoring of IOP in glaucoma, according to a press release.

The first patient has been implanted with the suprachoroidal-placed Eyemate-SC sensor in the international, multicenter, first-in-human ARGOS-SC01 study, the release said.

The Eyemate-SC is intended for implantation in glaucoma patients who do not need cataract surgery. The Eyemate-IO, which is intended for use in glaucoma patients who are undergoing cataract surgery, already has a CE mark.

“The successful inclusion of the first ARGOS-SC01 study patient is a pivotal milestone for Implandata towards broadening the use of our Eyemate system, eventually allowing also stand-alone implantation of our proprietary eye pressure-sensing devices,” Implandata CEO Max Ostermeier said in the release.

The study is expected to be completed by early 2020.